1.Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study.
Jingyi LI ; Yunsheng LIANG ; Wenli FENG ; Liehua DENG ; Hong FANG ; Chao JI ; Youkun LIN ; Furen ZHANG ; Rushan XIA ; Chunlei ZHANG ; Shuping GUO ; Mao LIN ; Yanling LI ; Shoumin ZHANG ; Xiaojing KANG ; Liuqing CHEN ; Zhiqiang SONG ; Xu YAO ; Chengxin LI ; Xiuping HAN ; Guoxiang GUO ; Qing GUO ; Xinsuo DUAN ; Jie LI ; Juan SU ; Shanshan LI ; Qing SUN ; Juan TAO ; Yangfeng DING ; Danqi DENG ; Fuqiu LI ; Haiyun SUO ; Shunquan WU ; Jingbo QIU ; Hongmei LUO ; Linfeng LI ; Ruoyu LI
Chinese Medical Journal 2025;138(16):2040-2042
2.Progress on haploidentical hematopoietic stem cell transplantation for the treatment of acquired severe aplastic anemia in children
Danqi LUO ; Yuhua QU ; Haiyan LIU ; Hua JIANG
Chinese Journal of Applied Clinical Pediatrics 2025;40(9):713-717
Acquired severe aplastic anemia (SAA) in children is a bone marrow failure disease characterized by reduced proliferation of marrow nucleated cells and decreased peripheral blood levels of two or three blood cell lines.Treatment options mainly include immunosuppressive therapy and allogeneic hematopoietic stem cell transplantation.The primary advantage of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is the availability of a donor for nearly everyone.With ongoing improvements in conditioning regimens, haploidentical hematopoietic stem cell transplantation has made significant progress.This paper aims to review the research progress on haplo-HSCT for treating acquired SAA in children, providing reference for clinical practice.
3.Progress on haploidentical hematopoietic stem cell transplantation for the treatment of acquired severe aplastic anemia in children
Danqi LUO ; Yuhua QU ; Haiyan LIU ; Hua JIANG
Chinese Journal of Applied Clinical Pediatrics 2025;40(9):713-717
Acquired severe aplastic anemia (SAA) in children is a bone marrow failure disease characterized by reduced proliferation of marrow nucleated cells and decreased peripheral blood levels of two or three blood cell lines.Treatment options mainly include immunosuppressive therapy and allogeneic hematopoietic stem cell transplantation.The primary advantage of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is the availability of a donor for nearly everyone.With ongoing improvements in conditioning regimens, haploidentical hematopoietic stem cell transplantation has made significant progress.This paper aims to review the research progress on haplo-HSCT for treating acquired SAA in children, providing reference for clinical practice.
Result Analysis
Print
Save
E-mail